Ocrelizumab and COVID-19

Patient safety is Roche/Genentech’s highest priority and we are closely monitoring the evolving coronavirus disease (COVID-19) situation. We believe that treatment decisions should be made between a patient and their treating neurologist/healthcare professional based on a benefit/risk assessment specific to the individual patient.

COVID-19 is caused by a new strain of coronavirus called SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), and although new findings and case studies around the impact of this virus continue to emerge, knowledge of the effect of SARS-CoV-2 on the general population and multiple sclerosis (MS) community remains limited.

Like many other disease-modifying therapies for MS, ocrelizumab works by making changes to the immune system.

Per the ocrelizumab US Prescribing Information (USPI; Section 5.2 Infections):

A higher proportion of ocrelizumab-treated patients experienced infections compared to patients taking REBIF or placebo. In RMS trials, 58% of ocrelizumab-treated patients experienced one or more infections compared to 52% of REBIF-treated patients. In the PPMS trial, 70% of ocrelizumab-treated patients experienced one or more infections compared to 68% of patients on placebo. Ocrelizumab increased the risk for upper respiratory tract infections, lower respiratory tract infections, skin infections, and herpes-related infections [see Adverse Reactions (6.1)]. Ocrelizumab was not associated with an increased risk of serious infections in MS patients.

In patients with active infections, treatment with ocrelizumab should be delayed until the infection is resolved.

Frequently Asked Questions

1. Do you believe that patients on ocrelizumab are at a higher risk of contracting SARS-CoV-2 infection and/or having a more severe course of COVID-19?
   - We are closely assessing emerging data, both our own pharmacovigilance data and real-world data (RWD).
     - Our pharmacovigilance data suggest that COVID-19 follows a similar course in ocrelizumab-treated patients with MS as in the general population.
     - Risk factors for severe COVID-19 in the general population include old age and presence of comorbidities, including hypertension, diabetes, obesity, smoking, and cardiovascular and lung diseases, which are likely to be similar in the MS population and those treated with ocrelizumab.
     - The known benefit/risk of ocrelizumab remains unchanged.
     - We are aware that emerging RWD from registries show varying findings on the impact of ocrelizumab treatment on the severity of COVID-19 in people with MS. The differences in these findings are to be expected because of the challenges of
collecting, analyzing, and interpreting RWD, and how healthcare systems in
different counties are being impacted by the pandemic.

- There has been no association between ocrelizumab and fatal COVID-19
  outcomes reported to date.
- From the limited RWD available globally, the general MS population does not
  seem to be at higher risk of contracting SARS-CoV-2.
- Major risk factors identified for fatal COVID-19 in the general MS population are
  advanced age (>55 years old), high levels of disability, a progressive form of MS,
  and comorbidities (eg, cardiovascular).
- The emerging RWD have not changed our position and assessment of the
  benefit/risk of ocrelizumab in patients with MS.

- We believe we need to continue to gather as much data as we can to help address
  limitations in RWD and get a clearer understanding of the impact of COVID-19 on
  patients treated with ocrelizumab in the absence of randomized, controlled trials to inform
  future recommendations.
- We believe that treatment decisions should be made between a patient and their treating
  neurologist or other medical professional based on a benefit/risk assessment specific to
  the individual patient.
- Physicians and patients should consult the ocrelizumab USPI for relevant information
  regarding the safety of ocrelizumab. For additional information and context surrounding
  the risk of infections, including COVID-19, with ocrelizumab, please consult the
  “Additional Information on Topics of Interest” section of www.ocrelizumabinfo.com.

2. Since your publication, have you received additional COVID-19 cases in ocrelizumab-
treated patients?

- Data previously shared in our recent publication is of validated reports of ocrelizumab-
treated patients with a confirmed or suspected SARS-CoV-2 infection and/or COVID-19
- As of May 31, 2020, we have received 201 validated reports as per standard
  pharmacovigilance activities relating to ocrelizumab-treated patients with a confirmed or
  suspected SARS-CoV-2 infection and/or COVID-19.
- For additional information, please consult the “Additional Information on Topics of
  Interest” section of www.ocrelizumabinfo.com.
- We actively support transparent safety communications (eg, congresses, publications,
  www.ocrelizumabinfo.com) and we are working with the MS community and independent
  external advisors to assess the most appropriate way to continue sharing our safety data
  related to COVID-19 infections with the community regularly in the coming months.

3. Do you recommend any change to patients’ treatment with ocrelizumab because of
COVID-19?

- We are actively discussing insights and perspectives related to MS and COVID-19 with
  the neurology community. Currently, there are only limited data available to inform
  specific recommendations or changes to treatment protocols for people treated with
  ocrelizumab.
- From our pharmacovigilance data, the risk factors for severe/fatal COVID-19 outcomes
do not indicate a difference between ocrelizumab-treated patients and the general
  population. The known benefit/risk of ocrelizumab remains unchanged.
We appreciate how difficult it may be for physicians and people with MS to make treatment decisions at this time, and we understand that some neurological and patient societies recommend the delay of treatment initiation or re-treatment. We believe that patients should speak with their neurologist or other medical professional before discontinuing or delaying treatment, so that decisions can be made based on a benefit/risk assessment specific to the individual patient.

4. What guidance can you provide for the treatment with ocrelizumab following a delay of a scheduled dose?
- The current clinical situation may necessitate to delay a scheduled dose of ocrelizumab due to logistical reasons or based on an individual benefit/risk decision.
- Per the ocrelizumab US Prescribing Information (USPI; Section 2.3 Recommended Dosage and Dose Administration):
  
  *Subsequent doses: single 600 mg intravenous infusion every 6 months.*

- Per the ocrelizumab USPI (Section 2.4 Delayed or Missed Doses):

  *If a planned infusion of ocrelizumab is missed, administer ocrelizumab as soon as possible; do not wait until the next scheduled dose. Reset the dose schedule to administer the next sequential dose 6 months after the missed dose is administered. Doses of ocrelizumab must be separated by at least 5 months [see Dosage and Administration (2.3)].*

- Based on very limited data available from the ORCHESTRA studies, there does not appear to be evidence that a delay in ocrelizumab dosing will increase the rate of infusion-related reactions with the next 600-mg dose administered as a single infusion.

5. Clinical trial data shows that patients on ocrelizumab have an increased risk of developing infections. How are you assessing the potential risk to ocrelizumab patients?
- COVID-19 is caused by a new strain of coronavirus called SARS-CoV-2, so knowledge about how it may affect people with MS and those treated with ocrelizumab is currently unavailable.
- Like many other disease-modifying therapies for MS, ocrelizumab works by making changes to the immune system.
- Per the ocrelizumab USPI (Section 5.2 Infections):

  *A higher proportion of ocrelizumab-treated patients experienced infections compared to patients taking REBIF or placebo. In RMS trials, 58% of ocrelizumab-treated patients experienced one or more infections compared to 52% of REBIF-treated patients. In the PPMS trial, 70% of ocrelizumab-treated patients experienced one or more infections compared to 68% of patients on placebo. Ocrelizumab increased the risk for upper respiratory tract infections, lower respiratory tract infections, skin infections, and herpes-related infections [see Adverse Reactions (6.1)]. Ocrelizumab was not associated with an increased risk of serious infections in MS patients.*

- Patient safety is Roche/Genentech’s highest priority. As a company we are closely following developments regarding COVID-19 and we are committed to keeping the MS
community updated with any new information to help inform health decisions related to ocrelizumab.

6. **Can you provide more detail about the upper and lower respiratory tract infections from Pivotal Clinical Trials?**
   - The upper and lower respiratory tract infections reported in patients treated with ocrelizumab were predominantly mild to moderate (80–90%).
   - The proportion of respiratory tract infections was higher in ocrelizumab-treated patients compared with those taking interferon beta-1a or placebo.
     - In the RMS clinical trials, 40% of ocrelizumab-treated patients and 33% of interferon beta-1-a-treated patients experienced an upper respiratory tract infection, and 8% of ocrelizumab-treated patients and 5% of interferon beta-1-a-treated patients experienced a lower respiratory tract infection.
     - In the PPMS clinical trial, 49% of ocrelizumab-treated patients and 43% of patients who received placebo experienced an upper respiratory tract infection, and 10% of ocrelizumab-treated patients and 9% of patients who received placebo experienced a lower respiratory tract infection.

7. **Which type of infections were generally observed during treatment with ocrelizumab?**
   - Rates of serious infection in all patients exposed to ocrelizumab in clinical trials remain consistent with rates of infection-related hospitalization in real-world MS cohorts.
     - Ocrelizumab was not associated with an increased risk of serious infections in patients with MS, as shown in our phase 3 clinical studies vs comparators (interferon beta-1a or placebo). Of those serious infections that occurred, the vast majority were bacterial, and the patients responded to standard of care treatment. Longer-term data through continued observation in our open-label extension studies have revealed no new or particular pattern of serious infections in patients with MS treated with ocrelizumab.
   - Ocrelizumab has been shown to have an increased risk of contracting certain infections, including upper respiratory tract infections that were predominantly mild to moderate (classified as non-serious).
     - A higher proportion of ocrelizumab-treated patients experienced non-serious infections compared with patients taking Rebif (interferon beta-1a) (58.5% vs 52.5%) or placebo (72.2% vs 69.9%). These infections were predominantly mild to moderate, were equally likely to be bacterial or viral, and resolved with standard of care treatment and in most cases patients remained on treatment with ocrelizumab.
8. Are there data that show how treatment with ocrelizumab affects the body’s ability to create an adaptive immune response?

- Per the ocrelizumab USPI (Section 7.2 - Vaccinations):

  A phase 3b randomized, open-label study (VELOCE) examined the concomitant use of ocrelizumab and several non-live vaccines in adults 18-55 years of age with relapsing forms of MS (68 subjects undergoing treatment with ocrelizumab at the time of vaccination and 34 subjects not undergoing treatment with ocrelizumab at the time of vaccination). Concomitant exposure to ocrelizumab attenuated antibody responses to tetanus toxoid-containing vaccine, pneumococcal polysaccharide, pneumococcal conjugate vaccines, and seasonal inactivated influenza vaccines. The impact of the observed attenuation on vaccine effectiveness in this patient population is unknown.

- In the VELOCE study, humoral responses were attenuated at all time points in patients who were B-cell depleted and received ocrelizumab compared with those who did not, but patients were nonetheless able to mount humoral responses to the vaccines and neoantigen studied. For more information, please go to the most recent ocrelizumab safety data (link here).